Language:

Systemic sclerosis

The Lancet (British edition), 2017-10, Vol.390 (10103), p.1685-1699 [Peer Reviewed Journal]

Elsevier Ltd ;2017 Elsevier Ltd ;Copyright © 2017 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Oct 7, 2017 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(17)30933-9 ;PMID: 28413064

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Systemic sclerosis
Author: Denton, Christopher P, Prof ; Khanna, Dinesh, Prof
Subjects: Classification ; Cytokines ; Disease control ; Evidence-Based Medicine ; Fibrosis ; Gene expression ; Health risk assessment ; Humans ; Immunosuppression ; Internal Medicine ; Morbidity ; Mortality ; Organs ; Patients ; Pulmonary hypertension ; Rheumatic diseases ; Rheumatology ; Scleroderma ; Scleroderma, Systemic - complications ; Scleroderma, Systemic - diagnosis ; Scleroderma, Systemic - mortality ; Scleroderma, Systemic - therapy ; Survival Analysis ; Systemic sclerosis ; Vascular diseases
Is Part Of: The Lancet (British edition), 2017-10, Vol.390 (10103), p.1685-1699
Description: Summary Systemic sclerosis, also called scleroderma, is an immune-mediated rheumatic disease that is characterised by fibrosis of the skin and internal organs and vasculopathy. Although systemic sclerosis is uncommon, it has a high morbidity and mortality. Improved understanding of systemic sclerosis has allowed better management of the disease, including improved classification and more systematic assessment and follow-up. Additionally, treatments for specific complications have emerged and a growing evidence base supports the use of immune suppression for the treatment of skin and lung fibrosis. Some manifestations of the disease, such as scleroderma renal crisis, pulmonary arterial hypertension, digital ulceration, and gastro-oesophageal reflux, are now treatable. However, the burden of non-lethal complications associated with systemic sclerosis is substantial and is likely to become more of a challenge. Here, we review the clinical features of systemic sclerosis and describe the best practice approaches for its management. Furthermore, we identify future areas for development.
Publisher: England: Elsevier Ltd
Language: English
Identifier: ISSN: 0140-6736
EISSN: 1474-547X
DOI: 10.1016/S0140-6736(17)30933-9
PMID: 28413064
Source: ProQuest One Psychology
AUTh Library subscriptions: ProQuest Central
MEDLINE

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Systemic sclerosis

Elsevier Ltd ;2017 Elsevier Ltd ;Copyright © 2017 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Oct 7, 2017 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(17)30933-9 ;PMID: 28413064

Searching Remote Databases, Please Wait